← back to search

O. Dereure

Hôpital Intercommunal de Créteil · FR
Area of research
Pathology and Forensic Medicine · Dermatology
Research interest
Research interests include Cutaneous lymphoproliferative disorders research, Autoimmune Bullous Skin Diseases, Lymphoma Diagnosis and Treatment, and Nail Diseases and Treatments.
h-index
47
citations
9,055
works
765
NIH funding
primary concept
Medicine
email

Recent publications

Solitary Oral Progression in a Well-controlled Sézary Syndrome.
2026cited by 0position: contributordoi
Severe Ulceronecrotic Evolution during Mogamulizumab Treatment in a Patient with Primary Cutaneous Peripheral T-cell Lymphoma.
2026cited by 0position: contributordoi
Atypical Neutrophilic Dermatosis Induced by Ibrutinib: A Dose-Dependent Cutaneous Adverse Reaction.
2026cited by 0position: contributordoi
Comparative analysis of progression free survival and treatment maintenance in patients with advanced melanoma responding to first-line treatment
EJC Skin Cancer 2026cited by 0position: contributordoi
Overall Survival After Allogeneic Transplantation in Advanced Cutaneous T-Cell Lymphomas (CUTALLO): A Propensity Score-Matched Controlled Prospective Study.
2025cited by 2position: contributordoi
Effectiveness, safety and reasons for discontinuation of sonidegib for patients with locally advanced basal cell carcinoma: A real-word evidence analysis from the French national registry CARADERM.
2025cited by 1position: contributordoi
Radiotherapy and prognostic factors in adnexal carcinomas: A retrospective study of 657 patients from the French CARADERM network.
2025cited by 1position: contributordoi
Prolonged complete remission of a lymphoepithelioma-like carcinoma of the skin with bone metastases induced by pembrolizumab.
2025cited by 0position: contributordoi
Increased risk of cutaneous squamous cell carcinomas in patients with Sézary syndrome: A nationwide multicenter retrospective study
Journal of the American Academy of Dermatology 2025cited by 0position: contributordoi
Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational cohort study
EClinicalMedicine 2024cited by 23position: middledoi
Sustained Remission Without Corticosteroids Among Patients With Pemphigus Who Had Rituximab as First-Line Therapy
JAMA Dermatology 2024cited by 22position: middledoi
Treatment of Bullous Pemphigoid with Avdoralimab: Multicenter, Randomized, Open-Labeled Phase 2 Study.
2024cited by 8position: contributordoi
Training Family Medicine Residents in Dermoscopy Using an e-Learning Course: Pilot Interventional Study.
2024cited by 5position: contributordoi
Annular Hailey–Hailey disease
JEADV Clinical Practice 2024cited by 1position: contributordoi
Training Family Medicine Residents in Dermoscopy Using an e-Learning Course: Pilot Interventional Study (Preprint)
2024cited by 0position: contributordoi
Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patients
British Journal of Dermatology 2023cited by 39position: middledoi
Effectiveness of mogamulizumab in patients with Mycosis Fungoides or Sézary syndrome: A multicentre, retrospective, real-world French study.
2023cited by 29position: contributordoi
Anti-BP180 IgG antibody ELISA values correlate with adverse pregnancy outcomes in pemphigoid gestationis.
2023cited by 7position: contributordoi
Efficacy and tolerance of photodynamic therapy with methyl‐aminolevulinic acid in early‐stage mycosis fungoides: A real‐life retrospective study
JEADV Clinical Practice 2023cited by 1position: contributordoi
Cutaneous vasculitis associated with mycosis fungoides.
2023cited by 0position: contributordoi
Improved prediction of the response duration to MAPK inhibitors in patients with advanced melanoma using baseline genomic data and machine learning algorithms
2023cited by 0position: contributordoi
Non-V600E/K BRAF Mutations in Metastatic Melanoma: Molecular Description, Frequency, and Effectiveness of Targeted Therapy in a Large National Cohort.
2022cited by 10position: contributordoi
A localized salt-dependent aquagenic urticaria successfully treated with omalizumab.
2022cited by 4position: contributordoi
Characterization of patients with advanced basal cell carcinoma progressing while receiving Hedgehog pathway inhibitors.
2022cited by 0position: contributordoi
Epidemiological changes in cutaneous lymphomas: an analysis of 8593 patients from the French Cutaneous Lymphoma Registry.
2021cited by 48position: contributordoi
Low-Dose IL-2 for Treating Moderate to Severe Alopecia Areata: A 52-Week Multicenter Prospective Placebo-Controlled Study Assessing its Impact on T Regulatory Cell and NK Cell Populations
Journal of Investigative Dermatology 2021cited by 33position: contributordoi
Lymphomatoid papulosis types D and E: a multicentre series of the French Cutaneous Lymphomas Study Group.
2021cited by 8position: contributordoi
Efficacy and safety of low-dose oral lenalidomide in refractory cutaneous lupus erythematosus: an open series of 19 cases.
2021cited by 3position: contributordoi
Carrying out local care for epidermal necrolysis: survey of practices.
2021cited by 3position: contributordoi
Towards a better understanding of adult idiopathic epidermal necrolysis: a retrospective study of 19 cases.
2021cited by 3position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 30 papers (2019–2026)M. Beylot‐Barry · Université de Bordeaux9 papers (2013–2025) · 7 papers (2021–2025)Saskia Ingen-Housz-Oro · Hôpitaux Universitaires Henri-Mondor6 papers (2021–2023)Nicolas Ortonne · Lymphoma Study Association5 papers (2021–2023)E. Maubec · Inserm4 papers (2013–2025)Florence Brunet‐Possenti · Inserm4 papers (2021–2026)F. Aubin · Endocrine Society3 papers (2013–2023)Florent Grange · Lymphoma Study Association3 papers (2013–2021)M. Bagot · Inserm3 papers (2021–2023) · 3 papers (2021–2023)Nadia Raison-Peyron · CHU Montpellier3 papers (2019–2022)Aurelie Du‐Thanh · Centre Hospitalier Universitaire de Montpellier3 papers (2019–2024) · 3 papers (2021–2025)Anne Pham-Ledard · Lymphoma Study Association3 papers (2021–2023)Philippe Saïag · Université de Versailles Saint-Quentin-en-Yvelines2 papers (2013–2019)L. Machet · Université de Tours2 papers (2013–2023)Nicole Basset‐Séguin · Inserm2 papers (2022–2025)Stéphane Dalle · Université Claude Bernard Lyon 12 papers (2013–2025)Lionel Moulis · CHU Montpellier, Univ Montpellier2 papers (2024–2024)